Display options
Cite
Qiao EQ, Yang HJ, Yu XF, et al. . Ann Transl Med. 2021;9(17):1389doi: 10.21037/atm-21-4199.
Qiao, E. Q., Yang, H. J., Yu, X. F., Gong, L. J., Zhang, X. P., & Chen, D. B. (2021). . Annals of translational medicine, 9(17), 1389. https://doi.org/10.21037/atm-21-4199
Qiao, En-Qi, et al. "." Annals of translational medicine vol. 9,17 (2021): 1389. doi: https://doi.org/10.21037/atm-21-4199
Qiao EQ, Yang HJ, Yu XF, Gong LJ, Zhang XP, Chen DB. . Ann Transl Med. 2021 Sep;9(17):1389. doi: 10.21037/atm-21-4199. PMID: 34733941; PMCID: PMC8506551.
Copy Download .nbib Format: NLM
Share it on

Ann Transl Med. 2021 Sep;9(17):1389. doi: 10.21037/atm-21-4199.

[No title available]

Annals of translational medicine

En-Qi Qiao, Hong-Jian Yang, Xing-Fei Yu, Li-Jie Gong, Xi-Ping Zhang, Dao-Bao Chen

Affiliations

  1. Department of Breast Tumor Surgery, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.

PMID: 34733941 PMCID: PMC8506551 DOI: 10.21037/atm-21-4199

Abstract

BACKGROUND: Triple-negative breast cancer (TNBC) is characterized by its aggressiveness and poor prognosis. Docetaxel is the common chemotherapeutic drug used in the treatment of TNBC. However, resistance to docetaxel has limited the effectiveness of TNBC treatment. Petroleum ether extracts of

METHODS: A docetaxel-resistant MDA-MB-231 (MDA-MB-231/docetaxel) cell line was established, and Cell Counting Kit-8 (CCK-8), quantitative real-time PCR (qRT-PCR), and western blotting assays were used to evaluate the effect of docetaxel resistance in MDA-MB-231 cells. Next, CCK-8 was also performed to detect the effect of docetaxel or the combination treatment of docetaxel and PECZ on the proliferation of MDA-MB-231/docetaxel cells. Thereafter, MDA-MB-231/docetaxel cells were subcutaneously injected into nude mice to induce a TNBC xenograft model, and the mice were divided into a model group, docetaxel group, PECZ group, and combination of docetaxel and PECZ group. Subsequently, hematoxylin and eosin (HE) staining, immunohistochemical, qRT-PCR, and western blotting were used to estimate the effect of pre-treatment with PECZ on docetaxel tolerance reversal.

RESULTS: PECZ significantly inhibited the expression of pregnane X receptor (PXR), multidrug resistance 1 (MDR1), breast cancer resistance protein (BCRP), and cytochrome P-450 (CYP3A4) in MDA-MB-231/docetaxel cells. Only higher concentrations of docetaxel could inhibit the viability of MDA-MB-231/docetaxel cells. When pre-treated with PECZ, lower concentrations of docetaxel could significantly inhibit cell viability. Meanwhile, combination treatment also reduced the tumor volume, ameliorated the pathological change of tumor tissues, and down-regulated the expressions of PXR, MDR1, BCRP, and CYP3A4 (according to HE staining, immunohistochemical, qRT-PCR and western blotting results

CONCLUSIONS: Our research showed that PECZ reversed docetaxel resistance in TNBC by PXR both

2021 Annals of Translational Medicine. All rights reserved.

Keywords: MDA-MB-231; Triple-negative breast cancer (TNBC); docetaxel-resistant; rhizoma zedoaria petroleum ether extract

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/atm-21-4199). The authors have no conflicts of interest to declare.

References

  1. Drug Metab Dispos. 2018 Sep;46(9):1361-1371 - PubMed
  2. BMC Cancer. 2020 Nov 10;20(1):1076 - PubMed
  3. Molecules. 2019 May 31;24(11): - PubMed
  4. Cancer Res. 2020 Dec 1;80(23):5355-5366 - PubMed
  5. J Control Release. 2017 Feb 28;248:96-116 - PubMed
  6. Breast Cancer Res. 2019 May 17;21(1):65 - PubMed
  7. Tumour Biol. 2014 Jul;35(7):6327-34 - PubMed
  8. Biochim Biophys Acta Gen Subj. 2018 Apr;1862(4):1017-1030 - PubMed
  9. Curr Pharm Des. 2019;25(8):871-935 - PubMed
  10. Evid Based Complement Alternat Med. 2014;2014:730678 - PubMed
  11. Breast Cancer. 2019 Mar;26(2):206-214 - PubMed
  12. Proc Natl Acad Sci U S A. 2014 May 27;111(21):E2182-90 - PubMed
  13. Exp Oncol. 2013 Dec;35(4):287-90 - PubMed
  14. Int J Oncol. 2010 May;36(5):1235-41 - PubMed
  15. FEBS J. 2011 Sep;278(18):3226-45 - PubMed
  16. Ann Oncol. 2015 Oct;26(10):2180-92 - PubMed
  17. BMC Cancer. 2018 Jul 6;18(1):718 - PubMed
  18. Breast. 2019 Nov;48 Suppl 1:S44-S48 - PubMed
  19. Anticancer Res. 2013 Apr;33(4):1421-8 - PubMed
  20. Ann Transl Med. 2020 Apr;8(7):499 - PubMed
  21. Pharmacol Res. 2009 Jun;59(6):365-78 - PubMed
  22. Front Pharmacol. 2020 Jun 09;11:835 - PubMed
  23. Cell Mol Life Sci. 2005 Apr;62(7-8):894-904 - PubMed
  24. Pharmacol Res. 2018 Sep;135:188-200 - PubMed
  25. Contemp Oncol (Pozn). 2017;21(1):83-89 - PubMed
  26. Planta Med. 2010 Aug;76(11):1075-9 - PubMed

Publication Types